## Vascular Dysfunction in Chronic Obstructive Pulmonary Disease (COPD): The Role of

## Mitochondrial-derived Oxidative Stress

Laura Mangone<sup>1</sup>, Ahram Ahn<sup>1</sup>, , Oh Sung Kwon<sup>1,2</sup>

<sup>1</sup>Department of Kinesiology, University of Connecticut, Storrs, CT, <sup>2</sup>Department of Orthopaedic Surgery & Center on Aging, University of Connecticut School of Medicine, Farmington, CT

## ABSTRACT

**Background:** This study sought to determine the contribution of mitochondrial-derived oxidative stress in the vascular dysfunction exhibited by patients with COPD.

**Methods:** Vascular function was assessed with brachial artery flow-mediated vasodilation (FMD) and the hyperemic response to both single and continuous passive leg movement (PLM) in 10 patients with COPD (55-70 years) before and after both the acute and chronic ingestion (4 weeks) of a mitochondrial-targeted antioxidant (MitoQ) (20mg/day).

**Results:** Baseline % FMD ( $2.5 \pm 0.9$  %) in the patients with COPD was significantly enhanced by both the acute ( $3.3 \pm 0.8$  %) and 4 week ( $5.3 \pm 1.2$  %) MitoQ consumption. Acute MitoQ had no effect on the single PLM-induced change in peak LBF ( $\Delta$ Peak) or the area under the leg blood flow (LBF) response curve (AUC), but the 4 week MitoQ consumption significantly augmented both the single PLM  $\Delta$ Peak (190±184 vs. 300±96 ml/min) and LBF AUC (20±14 vs. 50±16 ml). Compared to baseline ( $\Delta$ Peak = 300±84 ml/min; LBF AUC = 80±34 ml), both  $\Delta$ Peak and LBF AUC during continuous PLM-were significantly enhanced with both the acute ( $\Delta$ Peak: 435±96 ml/min; LBF AUC: 105±56 ml) and 4 week ( $\Delta$ Peak: 622±106 ml/min; LBF AUC: 300±120 ml) MitoQ consumption.

**Conclusions:** This study reveals that, in patients with COPD, mitochondrial-derived oxidative stress contributes significantly to the vascular dysfunction exhibited by this population. Therefore, targeting mitochondrial-derived oxidative stress may, through an improvement in vascular function, be an efficacious approach to combat cardiovascular disease in patients with COPD.